Patents by Inventor Aaron Nguyen

Aaron Nguyen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240417463
    Abstract: Provided herein are antibodies, masked antibodies (e.g., activatable antibodies), and antigen-binding fragments that target human CD47, polynucleotides encoding the same, therapeutic compositions thereof, and their use to treat CD47-positive diseases such as cancer. The masked antibodies described herein may comprise an IgG1 Fc region.
    Type: Application
    Filed: October 27, 2022
    Publication date: December 19, 2024
    Applicant: Adagene PTE. LTD.
    Inventors: Fangyong DU, Peter Peizhi LUO, Yan LI, Bin CAI, Jianfeng SHI, Jiangchun XU, Aaron NGUYEN, Songmao ZHENG, Guizhong LIU, Zhengxi DAI
  • COMBINATION THERAPY COMPRISING ANTI-CD137 ANTIBODIES
    Publication number: 20230242663
    Abstract: The present application provides compositions and methods for treating cancers in a subject using an anti-CD137 antibody and an agent that induces expression of CD137 on an immune cell and/or induces expression of CD137L on a cancer cell of the subject. In some embodiments, the agent is a cytokine such as IL-2. In some embodiments, the agent is a histone deacetylase (HDAC) inhibitor. In some embodiments, the agent is a DNA-damaging agent.
    Type: Application
    Filed: June 23, 2021
    Publication date: August 3, 2023
    Applicant: Adagene PTE. LTD.
    Inventors: Peter Peizhi LUO, Guizhong LIU, Aaron NGUYEN
  • Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
    Patent number: 10960005
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: March 30, 2021
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen
  • Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas
    Patent number: 10849898
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: December 1, 2020
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen
  • TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS
    Publication number: 20200297727
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Application
    Filed: June 10, 2020
    Publication date: September 24, 2020
    Applicant: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen
  • TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS
    Publication number: 20200113905
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Application
    Filed: December 10, 2019
    Publication date: April 16, 2020
    Applicant: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Jiangchun XU, Robert Cho, Aaron Nguyen
  • Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas
    Patent number: 10548896
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: February 4, 2020
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen
  • Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
    Patent number: 10543213
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: January 28, 2020
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen
  • TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS
    Publication number: 20190240223
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Application
    Filed: April 17, 2019
    Publication date: August 8, 2019
    Applicant: CELGENE CORPORATION
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen
  • TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS
    Publication number: 20190240222
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Application
    Filed: April 17, 2019
    Publication date: August 8, 2019
    Applicant: CELGENE CORPORATION
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen
  • Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
    Patent number: 10328077
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 25, 2019
    Assignee: Celgene Corporation
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen
  • TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS
    Publication number: 20180125844
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Application
    Filed: August 9, 2017
    Publication date: May 10, 2018
    Applicant: CELGENE CORPORATION
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen